FindTrial
Sign In

A DOUBLE BLIND STUDY, RANDOMIZED, CONTROLLED WITH ACTIVE CONTROLLER, MULTICENTER, PARALLEL GROUP, TEST OF CONCEPT OF L-454560 IN PATIENT WITH COPD.

A DOUBLE BLIND STUDY, RANDOMIZED, CONTROLLED WITH ACTIVE CONTROLLER, MULTICENTER, PARALLEL GROUP, TEST OF CONCEPT OF L-454560 IN PATIENT WITH COPD.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-021-03
Enrollment
15
Registered
2003-03-18
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

L-000454560 Type of group
2.5 mg of L-000454560 once a day. Group name:Placebo Type of group
Placebo of L000454560 will be administered.

Sponsors

MERCK SHARP & DOHME PERU S.R.L.,
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The patient is an outpatient male or female between 40 and 75 years of age in Visit 1. The patient has a consistent medical history of at least 1 year symptoms of intermittent or persistent COPD. The patient has a smoking history of> 10 packs per year

Exclusion criteria

Exclusion criteria: a. In the opinion of the researcher, the patient is mentally incapacitated or legally, what prevents obtaining informed consent, is incapable of read or understand written material or unable to comply with procedures of the study or protocol. b. The patient has a recent history ( 7 days) during the course of the study. e. The patient has had an important surgical procedure within 4 hours weeks before Visit 1.

Countries

Peru, United States

Contacts

Public ContactStela Lopez

MERCK SHARP & DOHME PERU S.R.L

stela_lopez@merck.com4115935

Outcome results

None listed

Source: REPEC (via WHO ICTRP)